$0.17
5.55% today
Nasdaq, Sep 19, 06:15 pm CET
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

GlycoMimetics, Inc. Stock price

$0.16
-0.01 3.64% 1M
-2.64 94.14% 6M
-2.20 93.05% YTD
-1.27 88.53% 1Y
-1.95 92.23% 3Y
-4.37 96.38% 5Y
-7.28 97.80% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
-0.00 0.61%
ISIN
US38000Q1022
Symbol
GLYC
Sector
Industry

Key metrics

Market capitalization $10.58m
Enterprise Value $-11.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.32
EV/Sales (TTM) EV/Sales -1,136.00
P/S ratio (TTM) P/S ratio 1,058.00
P/B ratio (TTM) P/B ratio 0.53
Revenue (TTM) Revenue $10.00k
EBIT (operating result TTM) EBIT $-40.88m
Free Cash Flow (TTM) Free Cash Flow $-35.72m
Cash position $22.39m
EPS (TTM) EPS $-0.61
P/E forward negative
Short interest 4.32%
Show more

Is GlycoMimetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

GlycoMimetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a GlycoMimetics, Inc. forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a GlycoMimetics, Inc. forecast:

Hold
100%

Financial data from GlycoMimetics, Inc.

Assets
Dec '23
44 44
Cash 42 42
Claims 0.18 0.18
Inventories - -
Other current assets Other current assets Current assets 1.82 1.82
1.53 1.53
Property, plant and equipment 0.77 0.77
Financial assets - -
Intangible Assets - -
Other fixed assets Other assets Fixed assets 0.76 0.76
Total Assets 45 45
Liabilities
Dec '23
Equity 38 38
6.90 6.90
Current liabilities 6.84 6.84
Non-current liabilities 0.07 0.07
Total Capital 45 45

In millions USD.

Don't miss a Thing! We will send you all news about GlycoMimetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GlycoMimetics, Inc. Stock News

Neutral
Business Wire
about 2 months ago
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the initiation of a strategic review and corporate restructuring plan. GlycoMimetics has engaged Lucid Capital Markets to act as a strategic advisor in the process. “We are ...
Neutral
Business Wire
4 months ago
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced comprehensive results from the company's pivotal Phase 3 study of uproleselan in R/R AML. “There is a wealth of data across large subsets of this pivotal Phase 3 study that ...
Neutral
Business Wire
4 months ago
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company's pivotal Phase 3 study of up...
More GlycoMimetics, Inc. News

Company Profile

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Head office United States
CEO Harout Semerjian
Employees 35
Founded 2003
Website www.glycomimetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today